SEC Form 4 · accession 0001209191-17-066475
NEKTAR THERAPEUTICS · NKTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen K Doberstein
Officer — SVP & Chief Scientific Officer
Period of report
Dec 15, 2017
Accepted (ET)
Dec 19, 2017 · 6:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000906709
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 15, 2017 | A | 26,000 | $0.00 | A | 69,820 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2 | $56.90 | Dec 15, 2017 | A | 65,000 | A | — | Dec 14, 2025 | Common Stock | 65,000 | 65,000 | D |
Explanation of responses
- F1This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service.
- F2This stock option vests over four years in equal monthly installments based on continued service.